Welgus Howard G. 4

What Happened
Howard G. Welgus, a director of Arcutis Biotherapeutics, sold 7,144 shares in open-market transactions on May 1, 2026. The weighted-average sale price was $22.99, for total proceeds of approximately $164,220. This was a sale (not a purchase or option exercise).

Key Details

• Transaction date: May 1, 2026; Form 4 filed May 5, 2026 (timely filing).
• Sale type/code: S (sale) — open market or private sale.
• Price: weighted average $22.99; actual trade prices ranged $22.79–$23.25 (footnote states per-price breakdown available on request).
• Total shares sold: 7,144; total proceeds ≈ $164,220.
• Shares owned after transaction: not specified in the supplied filing.
• Footnotes: Transaction was made pursuant to a 10b5-1 trading plan adopted March 11, 2025, with a plan end date of May 29, 2026. The filing includes a commitment to provide exact per-price quantities if requested.

Context
This sale was executed under a pre-established 10b5-1 plan, which typically schedules trades in advance and can indicate the sale was routine rather than a real‑time signal of the insider’s view. Sales are common for insiders for diversification or liquidity reasons; they are less informative than purchases about an insider’s confidence in the company.